-
1دورية أكاديمية
المؤلفون: Peters, Solange, Gettinger, Scott, Johnson, Melissa L, Jänne, Pasi A, Garassino, Marina C, Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A, Chaft, Jamie E, Carcereny Costa, Enric, Patel, Jyoti D, Chow, Laura Q M, Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A, Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta
المصدر: Peters, Solange; Gettinger, Scott; Johnson, Melissa L; Jänne, Pasi A; Garassino, Marina C; Christoph, Daniel; Toh, Chee Keong; Rizvi, Naiyer A; Chaft, Jamie E; Carcereny Costa, Enric; Patel, Jyoti D; Chow, Laura Q M; Koczywas, Marianna; Ho, Cheryl; Früh, Martin; van den Heuvel, Michel; Rothenstein, Jeffrey; Reck, Martin; Paz-Ares, Luis; Shepherd, Frances A; . (2017). Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). Journal of clinical oncology, 35(24), pp. 2781-2789. American Society of Clinical Oncology 10.1200/JCO.2016.71.9476
مصطلحات موضوعية: 610 Medicine & health
وصف الملف: application/pdf
العلاقة: https://boris.unibe.ch/111342Test/
-
2دورية أكاديمية
المؤلفون: van Tilburg, Cornelis Martinus, Kilburn, Lindsay Baker, Crotty, Erin, Smith, Amy Amundson, Perreault, Sébastien, Franson, Andrea Flynn, Jabado, Nada, Hoffman, Lindsey M., Schmidt, Rene, Schouten-van Meeteren, Antoinette Y.N., Sehestedt, Astrid, Opocher, Enrico, Hernáiz Driever, Pablo, Avula, Shivaram, Ziegler, David Simon, Qiu, Jiaheng, Tsao, Li-Pen, Manley, Peter, Hargrave, Darren R., Witt, Olaf
المصدر: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, pTPS10067-TPS10067, 1p